TaiMed Biologics, Inc. engages in the new drug development for human immunodeficiency virus (HIV). Its products include: (1) TMB-355 for the latter part of acquired immune deficiency syndrome (AIDS) medication. (2) TMB-360/365 for anti-AIDS virus. (3) TMB-607 Protease inhibitors for the anti-AIDS virus. The company was founded by David Ho, LanBo Chen and Ing-Wen Tsai on September 4, 2007 and is headquartered in Taipei, Taiwan.